BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 25 Jul 2026
Epitalon: The Telomere Tetrapeptide Heading Into Its First FDA Compounding Vote Tomorrow
Epitalon — a synthetic four-amino-acid peptide derived from pineal gland extract — faces its first formal FDA compounding review on 24 July 2026, the second day of the PCAC meeting at White Oak. With fresh independent evidence from a 2025 Biogerontology study, a negative FDA staff recommendation, and reported conflicts of interest on the panel itself, the regulatory moment is more contested than the peptide's three decades of largely preclinical research would suggest.
Read briefing →
Research Pipeline
Tesamorelin: The Only FDA-Approved GHRH Peptide — and What Its Regulatory Journey Tells the Research Community
Tesamorelin (Egrifta) stands apart from the peptides currently before the FDA's Pharmacy Compounding Advisory Committee: it already holds three successive FDA approvals, backed by Phase III randomised controlled trials. Understanding how it got there — and what that means for compounding access, off-label research, and the GHRH class more broadly — is increasingly relevant for procurement professionals as the July 2026 PCAC meeting unfolds.
25 Jul 2026
Regulatory & Policy
PCAC Votes to Recommend All Four Day-One Peptides Over FDA Scientists' Objections — What Comes Next for the Research Supply Chain
The FDA's Pharmacy Compounding Advisory Committee voted on 23 July to recommend BPC-157, KPV, TB-500 and MOTS-c for inclusion on the 503A Bulk Drug Substances List, defying its own career scientists on every substance. Day two votes on Semax, Epitalon and Emideltide followed on 24 July. A formal rulemaking process of eight to eighteen months now stands between the recommendations and any change in legal compounding status — and five further peptides await a second PCAC meeting before the end…
25 Jul 2026
Regulatory & Policy
FDA Advisory Panel Votes to Recommend BPC-157, KPV, TB-500 and MOTS-c for Compounding — Defying Its Own Scientists
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend four peptides — BPC-157, KPV, TB-500, and MOTS-c — for inclusion on the 503A Bulk Drug Substances List, against the agency's own staff recommendations. Day 2 votes on Emideltide, Semax, and Epitalon conclude today. The panel's recommendations are non-binding, and formal rulemaking could take twelve months or more.
25 Jul 2026
Research Pipeline
BPC-157: A 2026 Evidence Update on the Synthetic Pentadecapeptide Heading Into Its First Formal FDA Compounding Review
BPC-157 enters the 23–24 July 2026 FDA Pharmacy Compounding Advisory Committee meeting with a growing preclinical record, a fresh 2026 systematic review in PMC, and a newly registered Phase 2 randomised controlled trial — but still no published, independent RCT data in humans. This briefing sets out what UK research-procurement teams need to know about the peptide's mechanism, evidence base, and regulatory status on both sides of the Atlantic.
13 Jul 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With Four Decades of Russian Research Now Facing Its First FDA Compounding Review
Epitalon — a four-amino-acid synthetic peptide derived from pineal gland extracts — is scheduled for review by the FDA's Pharmacy Compounding Advisory Committee on 24 July 2026. With a research base spanning 40 years, proposed mechanisms ranging from telomerase activation to melatonin restoration, and an unresolved carcinogenicity question, it presents one of the most scientifically nuanced cases on the PCAC's agenda.
11 Jul 2026
Industry & Community
Macrocyclic Peptides: How a $1.8bn Novartis Deal and a String of Venture Rounds Signalled the Modality's Arrival in 2026
Macrocyclic peptides — ring-shaped molecules that sit between small molecules and biologics — have attracted more than $500 million in venture funding and several billion dollars in licensing deals in the first half of 2026. The capital surge reflects growing conviction that AI-assisted platform chemistry can now reliably produce oral macrocycles against targets that have resisted conventional drug design. Research procurement teams sourcing peptide compounds should understand what is driving…
10 Jul 2026
Research Pipeline
CJC-1295 and Ipamorelin: The Dual-Pathway GH Secretagogue Stack With a Decade of Preclinical Evidence and an Unresolved Regulatory Position
CJC-1295 and ipamorelin are among the most studied growth-hormone secretagogue peptides available for research procurement, each targeting a distinct receptor pathway. This briefing examines the pharmacology, available clinical evidence, US compounding status, MHRA position, and WADA classification that procurement teams need to understand before acquiring either compound.
09 Jul 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment With Deep Preclinical Roots and a Critical FDA Compounding Vote Fifteen Days Away
TB-500, a synthetic seven-amino-acid fragment of the endogenous protein thymosin beta-4, enters its most consequential regulatory moment on 23 July 2026, when the FDA's Pharmacy Compounding Advisory Committee votes on whether to recommend it for the Section 503A Bulk Drug Substances List. A June 2026 scoping review in Applied Sciences maps the evidence base: rich preclinical data, established veterinary use, and a critical absence of human RCTs for the injectable fragment itself — precisely…
08 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Wegovy Pill, Foundayo, and the NICE July Appraisal Mean for UK Research Procurement
The MHRA approved oral semaglutide (Wegovy pill) in June 2026 and a NICE committee is due to meet this month to assess orforglipron (Foundayo) for NHS use. With two mechanistically distinct oral GLP-1 agents now in or approaching the UK market, procurement teams need to understand the clinical differentiation, supply implications, and regulatory timelines that will shape research and clinical access.
07 Jul 2026
Research Pipeline
Semax: The ACTH-Derived Neuropeptide With 30 Years of Russian Clinical Use Now Facing Its First FDA Compounding Review
Semax is a synthetic heptapeptide derived from ACTH(4-10) with over three decades of approved clinical use in Russia for stroke recovery and cerebral ischaemia. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review it on 24 July 2026 — and the agency's own briefing documents, published last week, propose against listing it on the 503A Bulks List, citing insufficient human safety and efficacy data for injectable routes. Here is what the evidence record and regulatory outlook…
06 Jul 2026
Research Pipeline
Emideltide (DSIP): The 50-Year-Old Sleep Neuropeptide Facing Its First US Regulatory Scrutiny at the July 2026 PCAC
Emideltide — the FDA's compounding name for delta sleep-inducing peptide (DSIP) — is scheduled for review by the Pharmacy Compounding Advisory Committee on 24 July 2026. Despite more than four decades of sporadic research into sleep regulation and opioid withdrawal, its mechanistic basis remains poorly characterised and no randomised controlled human trial data exist. This briefing examines what the evidence base actually contains, where the regulatory process stands, and what…
05 Jul 2026